Patients and Interventions/Exposure : New users of semaglutide (n= 613) and liraglutide (n=4,144), which are GLP-1 receptor agonists approved for diabetes, and users of buproprion-naltrexone (n= 654), an Federal Drug Administration (FDA)-approved weight loss agent, which served as active comparator
1d) to a resolution of 1.09 (Fig
Does semaglutide work if I don't have diabetes
On the other hand, those who voted against were doctors and patient representatives
Kang N, Ma J, Zhou X, Fan X, Shang X, Huang Y
Personalized Medicine: Tailoring GLP-1 Therapy to the Individual Personalized medicine optimizes GLP-1 treatment by adapting to individual needs